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1. Introduction 
Pancreatic ductal adenocarcinoma (PDAC) is the fourth cause of cancer-related death in the 
US, accounting for an estimated 37.000 in 2010 (Jemal et al., 2010). Only about 10-15% of 
newly diagnosed PDAC are potentially resectable, while the majority of patients present 
with locally advanced or metastatic cancer. The median survival of non operable patients 
treated with standard chemotherapy ranges between 3 and 10 months, with less than 20% 
alive at 1 year (Van Cutsem et al., 2004a). Survival rates have not substantially improved 
during the past 25 years, and gemcitabine, currently considered as the standard for the 
treatment of patients with advanced PDAC, only offers a limited advantage over 5-
fluorouracil. Moreover, in these patients the tolerance of chemotherapy is often limited, due 
to the frequent occurence of pain and poor performance status. Given the limited efficacy of 
conventional chemotherapy, there is an urgent need of new treatment options for this 
disease. It is now clear that development and progression of PDAC is a complex process 
involving alterations of a core set of signalling pathways implicated in the regulation of 
multiple processes such as proliferation, cell cycle, migration, invasion, metastatization, 
metabolism, angiogenesis and resistance to apoptosis (S. Jones et al., 2008).  
This chapter will overview the more relevant cellular pathways involved in the 
development and progression of PDAC, and the results obtained in preclinical models and 
clinical trials with the use of novel agents specifically targeting them. 
2. Tyrosine kinases  
Proteins endowed with tyrosine kinase activity (TKs), i.e. able to transfer the terminal 
phosphate of ATP to the hydroxyl group of tyrosine on acceptor molecule, have long been 
established as key regulators of multiple cellular processes including cell growth, 
proliferation, migration, invasion and resistance to apoptosis. TKs include receptor tyrosine 
kinase (RTKs) and non-receptor TKs (NRTKs) (Natoli et al., 2010).  
2.1 RTKs 
RTKs are structurally divided in 20 subfamilies of single transmembrane alpha-helic 
proteins, with the exception of the IGFR family that retains a permanent dimeric 
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conformation. The binding of a specific ligand to the extracellular domain of the receptor 
induces receptor dimerization and autophosphorylation at a regulatory tyrosine within the 
intracellular activation loop of the kinase. This triggers a cascade of intracellular reactions 
that mainly follows the p42/p44 mitogen-activated protein kinase (MAPK) and the 
phosphatidylinositol 3 kinase (PI3K)/protein kinase B (AKT) pathways, and culminates 
with the activation of genes involved in cell proliferation and survival.  
2.1.1 MAPK and PI3K/AKT pathways 
In the MAPK pathway a pivotal role is played by Ras proteins (k-Ras, N-Ras and H-Ras), 
enzymes with intrinsic GTPase activity (Ramos, 2008). Ras proteins are attached to the 
plasma membrane by virtue of farnesyl or geranylgeranyl chains covalently linked to their 
C-terminal end. These post-translational modifications are essential for membrane-
anchorage and function of Ras. 
Following RTKs activation, a variety of proteins are recruited nearby the plasma membrane. 
The tyrosine phosphorylation of RTKs creates a specific binding site for the SH2 domain of 
adaptor proteins, such as Grb2, that in turn allows the recruitment of Guanine Nucleotide 
Exchange Factors (GEFs), such as SOS1. GEFs directly activate Ras by promoting the release 
of GDP and the binding of GTP. Activated (GTP-bound) Ras induces the activation of the 
Raf/MEK/MAPK signaling, and eventually of downstream transcription factors such as 
Jun/Fos. 
The key regulator of the PI3K/AKT pathway is PI3K, an enzyme that phosphorylates the 
membrane lipid phosphatidyl inositol 4,5-P2 (PIP2) in 3,4,5-P3 (PIP3). PIP3 is then 
responsible for AKT activation (Osaki et al., 2004). A negative regulator of this pathway is 
the Phosphatase and Tensin homolog (PTEN), that switchs off the signalling by 
dephosphorylating PIP3 in PIP2. 
PI3K is recruited to the plasma membrane by activated RTKs directly through its SH2 
domain, or indirectly through adaptor proteins such as Grb2/Gab1, or IRS1/2 in the case of 
IGFR. Once PI3K is activated and PIP3 is produced, the serine-threonine kinase AKT and the 
phosphoinositide-dependent kinase 1 (PDK1) are co-recruited to the plasma membrane, 
resulting in the phosphorylation and activation of AKT by PDK1. Activated AKT is able to 
phosphorylate multiple downstream targets, such as BAD, MDM2 and mTOR. In particular, 
phoshorylation of mTOR activates many biological processes essential for angiogenesis, cell 
metabolism and proliferation (Dowling et al., 2010). AKT activates mTOR complex 1 
(mTORC1) via the small GTPase, Rheb. In basal condition, Rheb activity is suppressed by 
the TSC1/TSC2 complex, a GTPase activating protein. AKT determines TSC2 
phosphorylation and inhibition of TSC1/TSC2 function, changes that unleash Rheb activity 
and mTOR signalling. Once activated, mTOR increases mRNA translation via two major 
downstream targets: the eIF4E-binding proteins (4EBPs) and the S6 kinases (S6K1 and 
S6K2). The 4EBPs are suppressors of the initiation translation factor eIF4E. After 
phosphorylation by mTOR, 4EBPs release eIF4E and make it available for the assembling of 
the eIF4F initiation complex that activates mRNA translation. In addition, the 
phosphorylation of S6K determines the subsequent phosphorylation of the ribosomal 
protein S6, a component of the 40S ribosomal subunit, that further facilitates mRNA 
translation. Proteins encoded by “eIF4E-sensitive mRNAs” include VEGF, cyclins, c-Myc 
and Bcl-xl, molecules involved in angiogenesis, cell proliferation and survival.  
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2.2 NRTKs 
Based on structure, at least 10 subfamilies of NRTKs have been identified (Natoli et al., 2010). 
ABL and Src families have been particularly investigated for their implication in hematological 
and non-hematological malignancies. Physiologically, these proteins play a critical role in 
relaying intracellular signalling to the nucleus, regulating RTKs downstream signals, MAPK 
and PI3K/Akt, and several other key pathways, such as focal adhesion kinase (FAK) and 
signal transducers and activator of transcription (STAT transcription factors). NRTKs are 
maintained in an inactive state by intramolecular autoinhibition or by cellular inhibitor 
proteins or lipids. They are activated by diverse intracellular signals, including recruitment to 
RTK, dissociation of inhibitors, and trans-phosphorylation by other kinases. Activated NRTKs 
critically participate in the regulation of cell proliferation, differentiation, migration, adhesion, 
angiogenesis, invasion, and immune function. 
2.3 Dysregulation of TKs signalling in PDAC 
Given the central role of TKs in the regulation of cell growth and survival, it is not 
surprising that TKs and/or their downstream signalling mediators are aberrantly activated 
in different types of cancers, including PDAC.  
In PDAC different RTKs have been shown to be frequently overexpressed, such as 
Epidermal Growth Factor Receptor (EGFR) in 90% (Lemoine et al., 1992), HER2 in 45-70% 
(Yamanaka et al., 1993b), Insulin-like Growth Factor-1 Receptor (IGF-1R) in about 50% 
(Bergmann et al., 1995), and cMET in 70% of the cases (M. Ebert et al., 1994). Overexpression 
is often reported to be associated with enhanced tumor growth, motility, invasion and drug 
resistance (M. Ebert et al., 1994; Freeman et al., 1995; Yamanaka et al., 1993a). 
Consistent with RTKs overexpression, the downstream MAPK and PI3K/AKT pathways are 
often activated in PDAC. Activation of the MAPK pathway has been shown to be 
responsible for the malignant transformation of pancreatic cells (Matsuda et al., 2002). 
However, activation of Ras in PDCA is mostly RTK-independent, since activating mutations 
of this oncogene occur in about 90% of cases in advanced disease (Hruban, 2001). Because of 
an impaired GTPase activity, mutated Ras maintains a GTP-bound state, resulting in a 
continuous activation of the downstream Raf/MEK/MAPK signalling. Activating mutation 
of Raf has also been described in pancreatic cancer (Hruban, 2001).  
Activation of PI3K/AKT pathway has been described in 50% of PDAC cases and is 
associated with a worse prognosis (Schlieman et al., 2003). PI3K has been shown to stimulate 
proliferation and to be involved in drug resistance of pancreatic cancer cells (Perugini et al., 
2000), while overexpression of AKT promotes invasion (Cheng et al., 1996) and expression 
of IGF-IR (Tanno et al., 2001).  
Among NRTKs, aberrant Src activation has been described in multiple malignancies, 
including pancreatic cancer (Dehm & Bonham, 2004), and shown to be related to increased 
cell motility and invasiveness (Shah & Gallick, 2007). 
The importance of TKs signalling in the maintenance of the neoplastic phenotype is 
emphasized by the fact that inhibition of these pathways induces cell-cycle arrest and 
apoptosis in preclinical models of pancreatic cancer (Asano et al., 2005; Bondar et al., 2002; 
Ng et al., 2002; Yip-Schneider & Schmidt, 2003). 
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2.4 TKs therapeutic targeting  
Preclinical studies have shown dependency of pancreatic tumor cell proliferation upon TKs 
activity and tumor regression by its blockade. 
In the last decade a number of molecules have been developed to inhibit TKs signalling. 
These agents can be divided into two major groups: small molecules that inhibit the catalytic 
activity of the kinase by interfering with the binding of ATP or substrates, and antibodies 
against RTKs or their ligands. In addition, other agents have been designed to block TKs’ 
downstream signalling molecules, in particular Ras, Raf, MEK, AKT and mTOR. The most 
relevant anti-TKs strategies applied in PDCA are detailed below, along with ongoing clinical 
trials. 
2.4.1 Anti-EGFR therapies 
Cetuximab, a chimeric monoclonal antibody that targets the extracellular domain of human 
EGFR, has been tested in a phase III randomized trial by the Southwestern Oncology Group 
(SWOG trial S0205) in combination with gemcitabine in patients with unresectable, locally 
advanced or metastatic PDAC. The study showed no significant improvement in overall or 
progression-free survival with the addition of cetuximab, with a minimal although 
significant advantage in time-to-treatment-failure (Philip et al., 2010). A similar study design 
was used to test the efficacy of panitumumab, a humanized anti-EGFR antibody 
(clinicaltrial.gov: NCT00613730). The study was early terminated based on the results of the 
S0205 trial. A randomized phase II trial of panitumumab, erlotinib and gemcitabine vs. 
erlotinib and gemcitabine in patients with untreated, metastatic PDAC (clinicaltrial.gov: 
NCT00550836) has been recently completed and results are awaited. 
Erlotinib, an EGFR tyrosine kinase inhibitor, has been tested in combination with gemcitabine 
in a randomized phase III trial (Moore et al., 2007). A very modest benefit in OS (median 6.24 
vs 5.91 months, P=.038) was observed compared with gemcitabine alone. Even if approved for 
the treatment of advanced PDAC, erlotinib is not routinely used because of increased toxicity 
and cost. Erlotinib is currently studied in the adjuvant setting (RTOG-led study 0848). 
Other EGFR tyrosine kinase inhibitors, including gefitinb and lapatinib, have been tested in 
pilot studies, but failed to demonstrate a clinically significant activity (Brell et al., 2009; 
Ignatiadis et al., 2006; Safran et al., 2008). 
2.4.2 Anti-HER2 therapies 
Trastuzumab, a recombinant humanized antibody directed against HER2 and largely used 
in the treatment of HER2-positive breast cancer, has been tested in combination with 
gemcitabine in 34 PDAC patients with HER2-overexpressing tumors. No significant survival 
benefit was observed (Safran et al., 2004). 
2.4.3 Anti-IGF-1R therapies 
Several trials testing the safety and activity of inhibitors of IGF-1R are ongoing. 
IMC-A12, an anti-IGF-1R monoclonal antibody, is currently being used in a randomized 
phase II study (SWOG 0727) in combination with chemotherapy and erlotinib in advanced 
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PDAC. The dual block of IGF-1R and EGFR has a strong preclinical rationale since the 
inhibition of IGF-1R might reverse resistance to anti-EGFR agents (Camirand et al., 2005). 
A study with the same design, carried out at the MD Anderson Cancer Center, is testing MK-
0646, a humanized monoclonal antibody against the IGF-1R (clinicaltrial.gov: NCT00769483). 
Finally, AMG-479, another anti-IGF-1R antibody, is being used in combination with 
gemcitabine in a three-arm randomized phase II study. Preliminary results have been 
presented showing a trend toward longer PFS in the combination arm (Kindler et al., 2010a). 
2.4.4 Anti-c-MET therapies 
AMG-102, a fully humanized monoclonal antibody against c-MET, has been tested in a 
phase I study in patients with advanced solid tumors, including pancreatic cancer (Gordon 
et al., 2010). The drug was safe and well tolerated and it is going to be tested in a phase II 
study, in monotherapy or in combination with other agents. 
2.4.5 Anti-MAPK therapies 
Tipifarnib, a Ras inhibitor, has been studied in combination with gemcitabine in a 
randomized phase III clinical trial (Van Cutsem et al., 2004b). The combination has an 
acceptable toxicity profile, but does not prolong overall survival in advanced PDAC as 
compared with single-agent gemcitabine. 
In a phase II study, Sorafenib, a TK inhibitor targeting Raf, VEGFR and PDGFR, has been 
tested in combination with gemcitabine in patients with advanced PDCA (Kindler et al., 
2010b), but failed to demonstrate clinical benefit. Other Raf inhibitors are currently tested in 
clinical trials (W. W. Ma & Adjei, 2009). 
CI-1040, an oral MEK inhibitor, has been used in a pilot phase II study in advanced tumors, 
including PDAC. Although generally well tolerated, CI-1040 demonstrated insufficient 
antitumor activity to warrant further development (Rinehart et al., 2004). 
2.4.6 Anti-PI3K/AKT therapies 
Clinical experience with inhibitors of the PI3K/Akt pathway in PDAC is mostly limited to 
mTOR or AKT inhibitors. Everolimus and enzastaurin failed to demonstrate significant 
clinical activity when tested in gemcitabine-refractory (Wolpin et al., 2009) or advanced 
PDAC (Richards et al., 2011), respectively.  
2.4.7 Anti-Src therapies 
Among NRTK-inhibitors, AZD0530, a Src kinase inhibitor, is currently being tested in a 
phase II trial in gemcitabine resistant patients and in a phase I/II trial in combination with 
gemcitabine in unresectable disease (clinicaltrial.gov: NCT00735917). 
3. Angiogenesis 
Angiogenesis, the process by which new blood vessels are formed from pre-existing ones, is 
critical for the growth, progression and metastatization of solid tumors, including PDAC.  
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This multistep process is tightly controlled by a fine-tuned balance between positive and 
negative regulators that emanate from cancer cells, endothelial cells, stromal cells, blood and 
the extracellular matrix. 
Although several positive regulators of angiogenesis have been described, vascular 
endothelial growth factor (VEGF or VEGF-A) represents the prototypical pro-angiogenic 
factor (Ferrara et al., 2003). VEGF belongs to a gene family which includes placental growth 
factor (PLGF), VEGF-B, VEGF-C and VEGF-D. When released mainly by tumor cells, VEGF 
binds two specific receptor tyrosine kinases, VEGFR-1 (de Vries et al., 1992) and VEGFR-2 
(Terman et al., 1992). This triggers receptor autophosphorylation and initiates a series of 
downstream signalling that promotes proliferation, survival and migration of endothelial 
cells.VEGFR-3 is also included in the same family of RTKs, but binds VEGF-C and VEGF-D 
(Karkkainen et al., 2002).  
Overexpression of VEGF has been associated with tumor progression and poor prognosis in 
several tumor types. The increasingly recognized importance of VEGF signalling in 
promoting tumor angiogenesis has led to the development and clinical validation of several 
agent that selectively target this pathway. Today, inhibition of angiogenesis is considered a 
valid treatment approach in a number of solid tumours, although with limited efficacy 
(Carmeliet & Jain, 2011).  
Agents affecting the VEGF pathway include drugs targeting VEGF itself (antibodies or 
“traps”) or the extracellular domain of VEGFR, small molecules targeting intracellular 
domains of VEGFR and those of other tyrosine kinases, and drugs inhibiting the 
intranuclear production of VEGFR mRNA, such as angiozyme. 
Bevacizumab, a humanized monoclonal antibody with a high binding affinity for circulating 
vascular endothelial growth factor A (VEGF-A), has been demonstrated to enhance the 
response rate, progression-free and overall survival of patients with advanced cancer when 
added to various chemotherapeutic regimens. The cellular mechanisms of action of 
bevacizumab are multifactorial and include inhibition of vascular neogenesis, vascular 
regression and normalization of tumour vasculature (Ellis & Hicklin, 2008). Several studies 
have shown that VEGF and its receptors are overexpressed in pancreatic cancer tissue and 
associated with liver metastases and poor prognosis (Kuehn et al., 1999; Seo et al., 2000). In 
PDAC, antiangiogenic therapy is still in an experimental phase with rare promising results. 
In the pre-clinical setting, inhibition of secreted VEGF by an antisense oligonucleotide led to 
decreased neoangiogenesis in a mouse xenograft model of pancreatic cancer resulting in 
reduced tumor growth and metastasis (Hotz et al., 2005). In the clinical setting, two 
randomized phase III trials of bevacizumab and gemcitabine (with or without erlotinib) 
failed to show any significant improvement of overall survival (Kindler et al., 2010c; Van 
Cutsem et al., 2009), and in one of them (Van Cutsem et al., 2009) only a marginal gain in 
progression-free survival was observed. The modest clinical benefit so far observed might 
be, at least in part, dependent on the development of resistance. Upregulation of 
compensatory angiogenic signalling pathways, such as those modulated by platelet-derived 
growth factor (PDGF) and fibroblast growth factor (FGF), has been suggested as a potential 
mechanism of resistance to anti-VEGF therapy (Casanovas et al., 2005).  
As opposed to isolated VEGF/VEGFR inhibition, multitargeted antiangiogenic TK 
inhibitors may more completely inhibit angiogenesis by blocking overlapping pathways 
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(Erber et al., 2004). A number of multitargeted antiangiogenic TK inhibitors are being tested 
in PDAC, including dual VEGFR/PDGFR and VEGFR/FGFR inhibitors (i.e. Sunitinib), as 
well as triple VEGFR/PDGFR/FGFR inhibitors (i.e. sorafenib), but limited activity in phase 
II trials ended further investigations on these agents. 
Axitinib, an oral and selective inhibitor of VEGFR 1,2 and 3 and PDGFR-β, has been 
investigated in a phase II randomized trial in PDAC, associated with gemcitabine versus 
gemcitabine alone (Spano et al., 2008). The trial showed a small, non-statistically significant 
gain in overall survival for the combination arm. A randomized double-blind phase III trial 
with a similar design has been recently completed (Clinicaltrials.gov: NCT00471146) and 
results are awaited. 
The persistent failure of anti-VEGF/VEGFR targeting in pancreatic cancer raises questions 
and concerns about choice of agents, trial design and our understanding of the biology of 
this disease.  
4. The hedgehog pathway  
The Hedgehog (Hh) signalling controls the proper tissue formation or “patterning” during 
normal embryonic development, modulating cell migration, proliferation and 
differentiation (Ingham & McMahon, 2001).  
The Hh signalling is mediated by three secreted proteins with high degree of homology, 
known as Sonic Hh, Desert Hh and Indian Hh. These proteins act in an autocrine/paracrine 
manner by binding the cellular transmembrane receptor Patched 1 (PTCH1). In the absence 
of the Hh ligand, PTCH1 inhibits the activity of another transmembrane protein, 
Smoothened (Smo), preventing its localization to the cell surface. After Hh binding, PTCH1 
is internalized and degraded, allowing Smo to translocate to the cell membrane where it 
initiates a downstream signalling responsible for the release of the glioma-associated (Gli) 
proteins from the inhibitor complex Suppressor of Fused (SUFU). The subsequent activation 
and nuclear translocation of Gli transcriptional factors results in increased expression of 
genes encoding for growth factors, cell cycle regulators, cell adhesion molecules, matrix 
proteins, other transcription factors, and inhibitors of the Hh pathway itself (Cohen, 2010; 
Ruiz i Altaba et al., 2002). 
A negative regulator of Hh pathway is Hh-interaction protein (HIP), a transmembrane 
protein that binds all 3 Hh proteins and prevent ligand inactivation of PTCH1 (Chuang & 
McMahon, 1999). 
Increased expression of the Hedgehog pathway components has been demonstrated in 
PDAC and its precursor lesions, indicating a role of this pathway during early stages of 
tumorigenesis (Morton et al., 2007). Moreover, reduced or absent expression of HIP is related 
to Hh signalling activation in pancreatic cancer cell lines (Martin et al., 2005). In a recent 
microarray study, nineteen altered genes of the Hh pathway were identified and 100% of 
tumors had alterations in at least one of the Hh pathway genes (S. Jones et al., 2008). 
Given the major role of Hh signalling in cancer development, the targeting of this pathway 
is considered a promising approach in the treatment of patients with PDCA. Indeed, in 
preclinical models, the inhibition of Hh signalling increased tumor cell apoptosis, decreased 
metastases, and significantly extended animal survival (Feldmann et al., 2008). 
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Currently, a phase I/II clinical trial is evaluating IPI-926, a small molecule inhibitor of Smo, 
in combination with gemcitabine in patients with previously untreated metastatic PDAC. 
(ClinicalTrials.gov: NCT01130142). Other agents targeting various components of the Hh 
pathway are in preclinical or early clinical development, including Hh antagonist and Gli 
inhibitor. 
5. DNA repair mechanisms 
Mammalian cells are constantly exposed to exogenous (e.g. ultraviolet or ionising radiation 
and genotoxic chemicals) and endogenous (e.g. cellular metabolism and free radical 
generation) stresses responsible for DNA damage (Hoeijmakers, 2001). In order to preserve 
genomic integrity, cells are equipped with several DNA repair mechanisms, including 
nucleotide-excision repair (NER), base-excision repair (BER), mismatch repair (MMR), 
homologous recombination (HR) and non-homologous end-joining (NHEJ) pathways. Loss 
of function in one of these pathways determines an increased rate of chromosome breakage 
and, as a consequence, activation of oncogenes by translocations, inactivation of tumor 
suppressor genes by deletions and amplification of drug resistance genes, thus fostering 
tumor progression and drug resistance. 
NER, BER and MMR pathways are involved in DNA single strand breaks (SSBs) repairing 
process, where the complementary DNA strand is intact and serves as a template 
(Hoeijmakers, 2001).  
In particular, NER acts on damaged nucleotides that distort DNA helix, such as pyrimidine 
dimers induced by UV or adducts formed by chemotherapeutic agents. Interestingly, this 
pathway may confer resistance to platinum-based chemotherapy.  
BER acts on nitrogenous bases damaged by reactive oxygen species or by spontaneous 
depurinations (Lindahl, 1993). Key enzymes in this pathway are PARP1 and PARP2, two 
nuclear proteins that catalyze the transfer of ADP-ribose units from intracellular NAD+ to 
nuclear acceptor proteins with the formation of ADP-ribose polymers.  
MMR removes mispaired nucleotides derived from replication error (Li, 2008) and is 
involved in the repair of DNA adducts such as those resulting from platinum-based 
chemotherapy (Kinsella, 2009). MMR pathway includes proteins encoded by different genes, 
such as MSH2, MSH3, MSH6, MLH1, MLH3, PMS1, and PMS2. It is noteworthy that an 
intact MMR pathway is required for cisplatin sensitivity, indicating a role for MMR proteins 
in the apoptotic signalling (Pani et al., 2007).  
On the contrary, HR and NHEJ pathways are recruited in the case of DNA double-strand 
breaks (DSBs), which are devoid of a viable chromatid template (Hoeijmakers, 2001). HR 
acts using sister chromatid as template, and therefore it functions only during the late S and 
G2 phases of the cell cycle, when a homologous region of DNA is available. HR repairs 
DNA DSBs caused by reactive oxygen species, ionizing radiation and certain antineoplastic 
drugs, such as bleomycin and anthracyclines. HR is initiated by the MRN complex which, 
thanks to its 3’-5’ exonuclease activity, exposes the 3’ ends on either side of the DSB (Zhong 
et al., 1999). Another complex, RPA, binds to the exposed single strand DNA to avoid 
degradation. Then, RAD51 is recruited at the site of DNA damage to initiate repair (Yu et 
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al., 2003). BRCA1 and BRCA2, known for their implication in familial breast and ovarian 
cancers, play an important role in this pathway. BRCA1 is required to retain RPA at the sites 
of DSBs (Durant & Nickoloff, 2005), while BRCA2 is required for RAD51 translocation (Yang 
et al., 2005). 
NHEJ repairs DSBs during G1/S phase of the cell cycle. This pathway is activated by the 
DNA-dependent protein kinase Ku70/Ku80 and requires additional proteins, including the 
artemis protein and DNA ligase IV, for proper conclusion (Meek et al., 2004).  
PDAC cells frequently harbor defects in DNA repair pathways, in particular as a result of 
BRCA2 or MMR gene mutation/deletion. BRCA2 mutation carriers have a 3-10-fold 
increased lifetime risk of developing PDAC (Shi et al., 2009). Germline BRCA2 gene 
mutations are responsible for approximately 10% of familial pancreatic cancer, whereas 
somatic mutations have been associated with 7–10% of sporadic PDAC (Shi et al., 2009).  
The discovery that FANCD1, one of at least 13 Fanconi anemia (FA) proteins interacting in a 
common pathway involved in HR, is identical to BRCA2, resulted in a search for mutations 
in other FA genes as possible pancreatic-cancer risk genes. Recently, a pancreatic cancer 
susceptibility gene, PALB2 (FANCN), has been found to encode for a BRCA2-stabilizing 
protein (Tischkowitz et al., 2009) and a germline deletion in the PALB2 gene has been 
described in a patient with familial PDAC (S. Jones et al., 2009). 
Alterations in the MMR genes have also been described in pancreatic cancer (Dong et al., 
2011). A direct consequence of MMR impaired function is microsatellite instability that 
makes the genome vulnerable to other specific genetic alterations. However, tumors of the 
pancreas with microsatellite instability are relatively rare as compared to other malignancies 
of the digestive tract, and represent only 5% of PDAC.  
Although abnormal DNA repair mechanisms critically contribute to tumor development 
and progression, they also provide a weakness that can be exploited therapeutically. In fact, 
tumors harboring defective DNA repair mechanisms might be particularly sensitive to 
DNA-damaging agents. For example, BRCA deficient cancer cells show increased sensitivity 
to agents causing DSBs, such as irradiation, mitomycin C, adriamycin, and cisplatin 
(Sonnenblick et al., 2011; van der Heijden et al., 2005). It has been shown that HR-deficient 
tumor cells, including those with defects in BRCA1/2, are highly sensitive to blockade of the 
BER pathway via inhibition of the PARP enzymes (Bryant et al., 2005; Farmer et al., 2005). In 
fact, PARP inhibitors (PARPis) lead to accumulation of SSBs that degenerate into stalled 
replication forks and, eventually, in DSBs, damage preferentially repaired by HR. Exposure 
of BRCA2-deficient murine tumors to PARPis resulted in a marked decrease in tumor 
growth and survival (Hay et al., 2009). A human pancreatic cancer cell line with defective 
BRCA2 function, CAPAN-1, has been shown to be very sensitive to the potent PARPis 
KU0058684 and KU0058948 (McCabe et al., 2005). The potential clinical application of PARP 
inhibition in BRCA2-related pancreatic cancer is encouraged by a recent published case 
report. A patient with a germline BRCA2 mutation affected by pancreatic cancer 
demonstrated a complete pathologic response after treatment with iniparib (BSI-201), a 
PARPi (Fogelman et al., 2011).  
As expected, PARPis have also been shown to significantly enhance the cytotoxicity of 
chemotherapeutic agents, such as cisplatin and 5-fluorouracil (De Soto & Mullins, 2011), and 
of radiotherapy (Tuli et al., 2011) in pancreatic cancer cell lines.  
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A phase I/II study of the PARPi veliparib (ABT-888) in combination with chemotherapy 
(modified FOLFOX-6), is currently being conducted in patients with metastatic pancreatic 
cancer (Pishvaian et al., 2011). Another phase I study is testing the safety and tolerability of 
the PARPi olaparib (AZD2281) in combination with gemcitabine in PDAC (clinicaltrials.gov: 
NCT00515866). The same drug is being used as monotherapy in a phase II trial in patients 
with advanced cancers, including PDAC, with confirmed genetic BRCA1 and/or BRCA2 
mutation (clinicaltrials.gov: NCT01078662). 
6. Histone deacetylase (HDACs) 
This large family of enzymes is composed of 18 members which are grouped into four 
classes according to their primary homology to similar yeast HDACs (de Ruijter et al., 2003). 
Classes I, II, and IV are structurally similar to the yeast proteins Hda1/Rpd3 and are zinc-
dependent for their catalytic activity (de Ruijter et al., 2003), while class III HDACs include 7 
different members of the sirtuin (SIRT) family and require NAD+ for their catalytic activity 
(Blander & Guarente, 2004). These families differ for subcellular localization, catalytic 
activity and susceptibility to different inhibitors. HDACs are known to play a key role in the 
epigenetic regulation of gene expression (P. A. Jones & Baylin, 2007). The process of 
deacetylation of histones by HDACs results in a closed chromatin structure, decreased 
access of transcription factors to promoter regions and repression of gene transcription 
leading to the silencing of tumor suppressor genes involved in cancer cell growth, 
differentiation and/or apoptosis (de Ruijter et al., 2003). Apart from regulating histone 
modification, HDACs also regulate the post-translational acetylation status of many non-
histone proteins involved in cancer cell proliferation, such as transcription factors, nuclear 
receptors and cytoskeletal proteins (Glozak et al., 2005).  
Dysregulation of HDACs has been detected in hematological malignancies and several 
different types of solid tumors (Federico & Bagella, 2011), including pancreatic cancer 
(Ouaissi et al., 2008; Ouaissi et al., 2011). 
During the 1990s, a clear link between the suppression of tumor cell growth and survival 
and the inhibition of HDAC activity was established (Xu et al., 2007), so that histone 
deacetylase inhibitors (HDACIs) have recently emerged as promising antineoplastic agents 
(Elaut et al., 2007). HDACIs can induce cell-cycle arrest, promote differentiation, and 
stimulate tumor cell death. Dimethyl sulfoxide (DMSO) and sodium butyrate (NaBu) are the 
first chemical agents identified as HDACIs (Friend et al., 1971) 
The preferential toxicity of HDAC inhibitors in transformed cells (Burgess et al., 2004; J. H. 
Lee et al., 2010) and their ability to synergistically enhance the anticancer activity of many 
chemotherapeutic agents (Sigalotti et al., 2007) has generated a great deal of interest in 
developing new HDACIs for cancer therapy. Indeed, several compounds, including pan-
HDAC inhibitors and class-selective or isoform-selective HDACIs, have been synthesized 
and tested in phase I, II and III clinical trials in cancer patients, either alone or in 
combination with other chemotherapeutic agents.  
Currently, two HDACIs are available for cancer treatment, suberoylanilide hydroxamic acid 
(SAHA or Vorinostat) (Vrana et al., 1999) and romidepsin (Khan et al., 2004) which have 
been approved by FDA for the treatment of cutaneous T-cell lymphoma. Vorinostat as well 
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as other HDACI such as Entinostat (MS-275) (Gojo et al., 2007) and MGCD0103 (Kell, 2007) - 
both of them in clinical trials (Kell, 2007; Tomillero & Moral, 2010) - have been shown to 
exert proapoptotic effects on pancreatic tumor cells and to chemosensitize them to 
gemcitabine (Arnold et al., 2007; Iwahashi et al., 2011; Sung et al., 2011). These drugs are 
now being tested in phase I-II trials recruiting advanced pancreatic cancer patients. 
7. Checkpoint kinase-1 (Chk1) 
The Chk1, downstream the nuclear protein kinase ataxia-telangiectasia mutated -ATM- 
(Kurz & Lees-Miller, 2004), arrests cells in the S- and G2-phases of the cell cycle in the 
presence of replication stress or DNA double-strand breaks, thus allowing cells to repair the 
damage (Koniaras et al., 2001). When this mechanism is defective, cells accumulate DNA 
damages which lead to apoptosis. p53-deficient cancer cells, rely on CHK1 for the damage 
response and agents able to disrupt this pathway could induce a specialized form of cell 
death known as mitotic catastrophe.  
Inhibitors of the Chk1 are currently in development with the aim to improve the efficacy 
and selectivity of a variety of DNA-damaging agents or antimetabolites (Bolderson et al., 
2009; Du et al., 2011; C. X. Ma et al., 2011). Recently, novel Chk1 inhibitors, such as 
AZD7762, have been shown to be able to sensitize pancreatic cancer cells and tumors to 
gemcitabine and are now in Phase I clinical trials (Morgan et al., 2010; Parsels et al., 2011) 
8. microRNAs 
Two main classes of RNAs are known: messenger RNAs (mRNAs), which are translated 
into proteins, and non-protein-coding RNAs (ncRNAs), whose function has been related to 
the regulation of intracellular and extracellular signalling involved in cell differentiation and 
development (Amaral & Mattick, 2008; Dinger et al., 2008).  
The following molecules have been included in the group of ncRNAs:  
 long ncRNAs, longer than 100 nucleotides, with a positive effect on regulation of gene 
expression (Orom et al., 2010); 
 small nucleolar RNAs (snoRNAs), able to modify or guide the pseudouridylation or the 
methylation of other RNAs (Mallardo et al., 2008); 
 small interfering RNAs (siRNA), regulating gene expression post-transcriptionally, by 
silencing specific mRNA molecules (J. Wang et al., 2010); 
 piwi-interacting RNAs (piRNA), involved in the silencing of retrotransposons in germ 
cells 
 riboswitches, a part of RNA that binds small molecule ligands (Siomi et al., 2011); 
 microRNAs (miRNAs), small (18–24 nucleotide in lenght) single stranded RNA 
molecules that negatively regulate gene expression (Bartel, 2004).  
Among all these regulatory ncRNSa, miRNAs are now acquiring a major relevance as 
potential therapeutic targets. miRNA were first discovered in Caenorhabditis elegans (R. C. 
Lee et al., 1993) and subsequently shown to be evolutionarily conserved genes (Moss, 2007), 
more than 1000 miRNAs being so far identified (miRBase database, release 17).  
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The biogenesis pathway of miRNA in animal cells is a complex multi-step process starting 
in the nucleus and (through many post-transcriptional modifications) ending in the 
cytoplasm to generate the mature, single stranded miRNA (Huang et al., 2011). miRNAs 
silence gene expression by binding to the 3'UTR of the target mRNAs with imperfect 
complementarity, thus causing repression of translation or inducing target mRNA molecule 
degradation, with consequent reduction or loss of the protein product (Carthew & 
Sontheimer, 2009; Huntzinger & Izaurralde, 2011). 
miRNAs have been shown to be missing or down-regulated in a variety of medical 
conditions including cancer, diabetes, and cardiovascular diseases (Medina & Slack, 2008; Z. 
Wang et al., 2011). For their role in cancer initiation and/or progression, miRNAs have been 
included in the family of genes recognized as tumor suppressors and oncogenes, with the 
name of oncomiRs or anti-oncomiRs (Iorio & Croce, 2009; Kent & Mendell, 2006). Moreover, 
because of these critical functions in the regulation of signalling pathways, miRNAs are 
regarded as new promising therapeutic targets for cancer treatment (Bader et al., 2011).  
Direct therapeutic approaches are based on the development of new drugs able to modulate 
miRNA expression levels, including:  
 miRNA mimics, to inhibit the expression of target protein-coding genes, for miRNAs 
whose expression is reduced in diseases (Kota et al., 2009) 
 miRNA inhibitors, with antisense constructs like antagomiRs, to increase gene expression 
(M. S. Ebert et al., 2007) 
However, there are still many problems to be solved, such as stability, effective in vivo 
delivery systems, and selectivity. 
These therapeutic strategies could be of high relevance for pancreatic cancer treatment. 
Recently, deregulation of miRNAs expression has been correlated to diagnosis, prognosis and 
chemotherapy resistance of pancreatic cancer (Chakraborty et al., 2011; Dhayat et al., 2011). 
Among the several miRNAs reported to be up regulated in pancreatic cancer such as miR-21, 
miR-221/222, miR-25, miR-27a, miR-210, miR-200b, miR-148a,b, miR-196a-2, miR-155, and 
members of the miR-17-92 family (Chakraborty et al., 2011; Liffers et al., 2011; Nana-Sinkam & 
Croce, 2011; Zhang et al., 2011), the oncomiR miR-21 appears of high relevance as potential 
therapeutic target in pancreatic cancer, regulating proliferation, invasion, apoptosis and 
chemosensitivity (Ali et al., 2010; Giovannetti et al., 2010; Hwang et al., 2010; Park et al., 2009). 
miR-21 mimics, transfected into MIA PaCa-2 pancreatic cancer cells, have been shown to 
upregulate Bcl-2, to downregulate Bax expression, to decrease chemosensitivity to gemcitabine 
and to increase proliferation as compared with control cells. Transfection with miR-21 
inhibitors had opposite effects, decreasing cell proliferation (J. Dong et al., 2011). 
Further, miRNA-based biomarkers have a significant impact on the development of 
treatment strategy that combines therapeutics with diagnostics, a concept known as 
theranostics (Pene et al., 2009) and are highly relevant for drug development and 
personalized medicine. 
9. Conclusion 
In the last decade, a variety of molecularly targeted agents potentially useful in the 
treatment of PDAC have been developed. However, in contrast with the encouraging results 
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obtained in animal models, results in humans have been quite disappointing. The still 
limited knowledge of the molecular pathogenesis of PDAC, the inappropriateness of the 
experimental models, the suboptimal combinations and schedules selected for clinical trials 
can be suggested as possible reasons for this failure. Given the complexity of the molecular 
pathogenesis of PDAC, it is very likely that a substantial improvement of clinical outcome 
can derive from the rational targeting of more than a single altered pathway.  
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